---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-161662"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:21:48.104308+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma prices $50M registered direct offering of 12.5M ADS at $3.99/ADS

## Summary
- Gross proceeds $50M from 12,531,300 ADS at $3.99 each; net proceeds ~$45.9M after expenses.
- Underwriters: Jefferies, Leerink Partners, and Cantor Fitzgerald acting as joint book-runners.
- New investors include Frazier Life Sciences, Deerfield Management, and Perceptive Advisors; existing holder participation.
- Net proceeds to fund setrusumab program (supply and pre-launch in Europe) and general corporate purposes.
- Offering expected to close on June 17, 2024, subject to customary conditions.

## SEC filing metadata
- accession: 0001193125-24-161662
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312524161662/0001193125-24-161662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312524161662/d828399d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-161662
- JSON: https://secwatch.observer/filing/0001193125-24-161662.json
- Plain text: https://secwatch.observer/filing/0001193125-24-161662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.